Revisiting the Potential of Ayurvedic Medicinal Herbs, Neem (Azadirachta indica) and Giloy (Tinospora cordifolia) for Prevention against COVID-19

Mayank Chaudhary1 • Arvind Singh Farswan2 • Vivekanand Bahuguna3*
1Department of Biotechnology, Maharishi Markandeshwar (Deemed to be) University, Mullana-Ambala-133207, Haryana, INDIA
2College of Pharmacy, Shivalik Campus, Dehradun-248 007, Uttarakhand, INDIA
3School of Biological Sciences, Doon University, Dehradun-248012, Uttarakhand, India

*Corresponding author: vn1bahuguna@gmail.com

Received: 30.11.2021; Revised: 27.12.2021; Accepted: 28.12.2021
©Society for Himalayan Action Research and Development

Abstract: Current pandemic of coronavirus disease 2019 (COVID-19) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in huge global mortality with daily increment of cases. Though at present different vaccines are available but complete vaccination at the country level needs subsequent time interval. In present condition of stress and fear, bioactive compounds from different medicinal plants are screened using computational approaches to be used as a potential drug candidate. These in silico approaches have found few phyto-compounds that can be used against therapeutic protein targets of SARS-CoV-2. These natural compounds might have fewer side effects compared to chemotherapeutic agents that are re purposed in this pandemic situation. Though convincing results are obtained from in silico approaches but it warrants further studies to be marketed as a recommended drug. Foreseeing the current pandemic and positive computational results on natural products, these can be considered for enhancing immunity and prevention. Decoction of therapeutically beneficial medicinal plants like neem (Azadirachta indica) and giloy (Tinospora cordifolia) can be recommended due to easy availability, cost effective nature and easy implementation at community level. These natural products possess anti-inflammatory, antipyretic, fungicidal and antiseptic properties which can prevent from COVID infection and post-COVID complications, including attack from opportunistic pathogens.

Keywords: COVID-19, Decoction, Phytocompounds, SARS-CoV-2, Neem, Giloy

Introduction

COVID-19 Coronavirus (CoV) belongs to Coronaviridae family of RNA viruses (Umakanthan et al. 2020) causing respiratory, gastrointestinal and hepatic diseases in both animals and humans (Weiss and Leibowitz 2011). CoV is responsible for major outbreaks like severe acute respiratory syndrome (SARS) and middle-eastern respiratory syndrome (MERS) over past two decades (Harrison et al. 2020). Out of different genera of CoV (α,β, γ and δ), only α and β genera have been reported to infect mammals (Guo et al. 2020). CoV comprises of positive-sense, single stranded RNA genome (Van der Hoek et al. 2004) where 5’ terminus codes for proteins involved in viral replication and 3’ terminus contains structural proteins. These include spike protein (S), membrane protein (M), envelope protein (E), nucleocapsid protein (N) and haemagglutinin-esterase (HE) protein (Delmas and Laude 1990; Beniac et al. 2006). Interaction between Spike protein (S) of CoV and human angiotensin converting enzyme 2 (ACE2) receptor mediates attachment and fusion of virus to host cell membrane (Li et al. 2003). Initial reports about novel coronavirus came from the Wuhan city of China in December, 2019 (Xu et al. 2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was found as the causative agent and World Health Organization (WHO) named the
disease as coronavirus disease 2019 (COVID-19) (Ji et al. 2020). SARS-CoV-2 which belongs to β genera of CoV is an enveloped, non-segmented, positive-sense RNA virus. Genome sequencing results has suspected transfer of SARS-CoV-2 from bats to humans through pangolins (Manis javanica) (Chaudhary 2020). Later on, WHO declared COVID-19 as a pandemic on 11th of March, 2020 and at present it has affected more than 200 countries worldwide. Infection by SARS-CoV-2 involves cleavage of S protein at S1/S2 protease cleavage site (Wang et al. 2020). S1 subunit causes binding of virus to host cells whereas S2 subunit is critically involved in membrane fusion (Walls et al. 2020). S1 subunit constitutes N-terminal domain (NTD) and receptor binding domain (RBD) whereas S2 comprises of fusion peptide (FP), heptad repeat 1 (HR1), central helix (CH), connector domain (CD), heptad repeat 2 (HR2), transmembrane domain (TD) and cytoplasmic tail (Wang et al. 2020). Upon binding to ACE2, spike protein (S) of SARS undergoes conformational change to be targeted for proteolytic cleavage (Li et al. 2006). Trimming by cathepsin (Simmons et al. 2005) or by type II transmembrane serine proteases (TTSPs) including transmembrane protease serine 2 (TMPRSS2) and human airway trypsin-like protease (HAT) activates spike protein (S) of SARS-CoV (Matsuyama et al. 2010). Abundant expression of ACE2 protein in epithelia of lung and intestine (Hamming et al. 2004) along with mucosa of oral cavity (Xu et al. 2020) provide possible route of entry. Greater infectivity and transmissibility of SARS-CoV-2 is because of its higher binding affinity to ACE2 receptor in comparison to SARS-CoV which caused SARS and MERS (Wrapp et al. 2020; He et al. 2020). This enhanced binding affinity of SARS-CoV-2 for ACE2 is responsible for its ability to target nasopharyngeal and oropharyngeal tissues as abundant expression of ACE2 is found in human mucosal and oral tissues (Hamming et al. 2004; Xu et al. 2020).

SARS-CoV-2 infection manifests flu-like symptoms leading to acute respiratory distress (ARDS), pneumonia, renal failure and death (Harrison et al. 2020). COVID-19 infection is not age restricted so individuals belonging to different age groups are at potential risk (Chao et al. 2020). Initiation of COVID-19 with mild symptoms can culminate in life threatening systemic inflammation and multiorgan damage (Harrison et al. 2020). As of October, 2021, more than 50 lac global deaths due to COVID-19 have been reported and the number of infected individuals is increasing at a rapid pace. In the context of Indian scenario, the death toll crossed 4.5 lac mark making India third most affected nation on the basis of mortality. Though the government is applying strict and appropriate measures to tackle this pandemic with betterment in the medical sector and initiation of vaccination drive but self-care should be employed till complete vaccination is achieved. So consumption of natural products...
and decoction can be considered as a more simple and economical measure at present. With the vast therapeutic potential, medicine systems like Ayurveda and Yoga can prove effective adjuvant therapy of COVID-19 (Golechha 2020).

Ayurveda is a traditional Indian medicine system which originated many thousand years ago. It not only focuses on curing the disease but also prevents development of any illness (Mukherjee et al. 2017). Ayurveda comprises of ayur (life) and veda (science or knowledge). Details about management of epidemic and immunity as critical criteria to either prevent or arrest progression of disease is very well documented in Charaka Samhita which is a classic Ayurveda text (Golechha 2020). Prophylaxis measures like consumption of herbal decoctions and hot water along with gargling and steam inhalation is well described in Ayurveda for respiratory illness (Chandran et al. 2018). These simple and affordable Ayurvedic interventions can be easily implemented on wider scale (Golechha 2020).

In India, the Ministry of Ayush released guidelines to boost immunity and self-care by applying Ayurvedic principles (Ministry of Ayush, 2020). As a result of this, many individuals are taking decoctions (Kadha) and following routine practices of gargling with hot water and steam inhalation as a preventive measure against current COVID-19 pandemic.

Natural Products with Therapeutic Potential

Medicinal plants contain different phytochemicals with enormous therapeutic potential. Vast research is also focused on extraction of these phytochemicals and exploring their efficacy and action (Fig.1:Thota et al. 2020). Different dietary supplements and home-made remedies have great potential to prevent against acute respiratory infections. In addition to prevention, these agents also enhance the immunity to fight against various infectious agents. These home-based remedies harness great therapeutic potential against respiratory infections. Thota et al. (Op cit) described about the main bioactive compound present in home-based remedies (like ginger, garlic, onion, turmeric, neem, basil, pepper) along with their molecular mechanism. Proteases of SARS-CoV targets TGF-β1 (transforming growth factor beta 1) and NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) for the activation of downstream effector proteins in order to induce fibrosis (Li et al. 2012; Kim et al. 2013; Kobayashi et al. 2014) and release of inflammatory cytokines (Fu et al. 2020). Bioactive compounds from such home-based remedies inhibit the activation of TGF-β1 and NF-κB as a preventory measure. Current research focuses on computational studies targeting molecular docking to select out the best possible phytochemical from different medicinal plants to be used against SARS-CoV-2.
Medicinal plants as Potential Candidate

Neem (*Azadirachta indica*) and Giloy (*Tinospora cordifolia*)

Neem (*Azadirachta indica*) is a precious medicinal plant which has been used to cure many acute and chronic diseases (Gupta et al. 2017). Over hundreds of chemically diverse and structurally complex phytochemicals have been isolated from neem (Subapriya and Nagini 2005). Phytochemicals extracted from different parts of neem are categorized into isoprenoids (like diterpenoids, triterpenoids, limonoids) and non-isoprenoids (like proteins, polysaccharides, polyphenolics, tannins and aliphatic compounds) (Brahmachari 2004). Some of the triterpenoids isolated from neem exhibits vast therapeutic potential including anti-inflammatory, antipyretic, fungicidal and antiseptic properties. Neem and its constituents are found to modulate the regulation of various signalling pathways (Gupta et al. 2017). Some of the targets of neem are those involved in the progression of COVID-19 (Fig.2: Gupta et al. Op cit). The additional potential of neem against diabetes and hypertension along with antifungal properties can be exploited as these have been commonly reported as post-COVID complications in the recovered patients. Both *in vivo* and *in vitro* studies highlighting the potential of neem against diabetes and hypertension are available (Gupta et al. 2017).

Giloy (*Tinospora cordifolia*) is also a well-established Ayurvedic medicinal plant used in traditional Indian system of medicine (ISM) to treat various complications of human body (Sharma et al. 2019). It has huge applicability in enhancing body's resistance power and immunomodulation by improving innate immunity. It possesses anti-inflammatory, analgesic and anti-pyretic activities (Husain et al. 2015; Philip et al. 2018). Giloy possess numerous crucial phytochemical compounds including terpenoids, alkaloids, phenolics, lignans and steroids (especially, tino cordiside, tinosporine, diterpenoid) (Singh and Chaudhari 2016; Sharma et al. 2019). These phytocompounds enrich giloy with antioxidant, hypoglycemic, antiviral and immunomodulatory activities. Moreover, different components of giloy like leaves, stem and roots have been found to be effective against variety of diseases (Singh and Chaudhari 2016; Sharma et al. 2019).
*Tinospora* also possess terpenoids that has huge potential against respiratory tract infections (Sharma et al. 2019; Antul et al. 2019).

Further, Tinosporin and diterpenoid has potential role against different subgroups of retroviruses (Singh and Chaudhari, 2016). During current pandemic different computational approaches like molecular docking, molecular dynamics simulations and others are adopted for screening of potential molecules/drugs from various databases. It also involves screening of phytochemicals from different medicinal plants in search of identifying the most effective compound against therapeutic protein targets of SARS-CoV-2. Protein targets of SARS-CoV-2 that are being considered include 3CLpro (chymotrypsin like main protease), PLpro (papain-like protease), SGp-RBD (spike glycoprotein- receptor binding domain), RdRp (RNA dependant RNA polymerase) and ACE2 (angiotensin-converting enzyme 2) (Vardhan and Sahoo 2020). As a result numerous molecular docking studies are ongoing in order to identify the most potent phytochemical that can be used as an effective anti-viral drug.

ACE2 is the main receptor through which spike (S) protein of SARS-CoV-2 interacts after its trimming by TMPRSS2 (transmembrane protease serine 2). Phytochemicals from neem (*Azadirachta indica*) and *Aloe barbadensis* were screened against TMPRSS2 protein using molecular docking study (Senapati et al. 2021). Nimbochalsin from *A. indica* was found to be the most stable lead compound among others. Similarly, 154 phytochemicals were screened from limonoids and triterpenoids that can show inhibitory effects against SARS-CoV-2. Study involved molecular docking, *in silico* ADMET and protein-ligand interaction to reduce the number to seven phytochemicals for final screening as potent inhibitors of SARS-CoV-2. Majority of the finally selected phytochemicals screened against therapeutic protein targets of SARS-CoV-2 proved effective against each of the therapeutic target protein with glycyrrhizic acid as the most potent phytochemical targeting active site of all the studied protein targets (Vardhan and Sahoo 2020). Identical to these, another study aimed to find an effective plant- based treatment for COVID-19 screened 38 bioactive compounds from five different plant sources including *A. indica*. These compounds were subjected to molecular docking against the main protease of SARS-CoV-2. Out of all the studied compounds, gedunin was found to be comparatively most potent (Garg et al. 2020).

![Fig. 2 Molecular Docking Studies for Potential Drug Candidate](image-url)
Another study by Adegbola et al. (2021) screened compounds from three plants against proteins of SARS-CoV-2 including PLpro (papain like protease), 3CLpro (chymotrypsin like main protease) and TMPRSS2. The study found various compounds from *A. indica* as potential drug candidates possessing good pharmacokinetics and toxicity profile. Similarly, Ogidigo et al. (2020) screened natural phytochemicals from *A. indica* and *Momordica charantia* L. as possible inhibitors against SARS-CoV-2 protease. Their study compared the inhibition potential of selected phytochemicals with food and drug administration (FDA) approved reference anti-viral drugs. Other molecular docking studies have also screened compounds from neem and other plants as suitable candidates against SARS-CoV-2 (Borkotoky and Banerjee, 2020; Baildya et al. 2021; Gogoi et al. 2021).

Similarly, in context of current scenario, molecular docking studies have also found convincing results on therapeutic potential of phytochemicals from giloy. Tinocordiside (phytocompound from *Tinospora*) was found to be effective against ACE2-RBD complex. This highlighted the fact that Tinocordiside can prevent entry of SARS-CoV-2 into the host cell by interrupting the interaction between receptor binding domain (RBD) of virus and host ACE2 receptor (Balkrishna et al. 2021a). Inhibitory potential of Tinocordiside against SARS-CoV-2 was further found by Shree et al. (2020) in addition to five other potential phytocompounds from Ashwagandha (*Withania somnifera*) and Tulsi (*Ocimum sanctum*). Further, *in silico* study using molecular docking was done to identify the interaction of constituents of giloy (berberine, β-sitosterol, coline, tetrahydropalmatine, octacosanol) with 3CLpro (protease of COVID-19 virus) to identify most suitable anti-viral compound (Chowdhury 2020). The study revealed berberine as the most potent phytocompound to target viral replication. In addition to these molecular docking studies, aqueous extract of *T. cordifolia* in form of Giloy Ghanvati reversed the damage caused by introduction of spike protein of SARS-CoV-2 in humanized zebrafish model (Balkrishna 2021b). Experimental design involved humanization of zebrafish by transplantation of A549 cells into the swim bladder with subsequent induction of recombinant spike protein of SARS-CoV-2 at the site of A549 cell xenograft to manifest disease phenotype. Oral infusion of Giloy Ghanvati reversed infiltration of pro-inflammatory immune cells, renal damage and abnormal behavioural fever in the treated group (Balkrishna 2021b). This study validated the results of molecular docking studies showing therapeutic potential of giloy against current pandemic.

Though most of the molecular docking studies found phyto-compounds as potential drug candidates, but all these computational results warrants both *in vitro* and *in vivo* studies to determine effectiveness of identified compounds as a potent cure for COVID-19. Moreover, such molecular docking results hints on the use of decoction as a preventory
measure. It is cheap, more accessible and can be implemented easily in homes by the time efficacy of any such plant based drug is proved through clinical trials before being marketed which requires a considerable amount of time.

Decoction of Neem and Giloy in COVID and Post-COVID Time

With rapid spread of COVID-19 and limitations of ongoing vaccination drive, prevention should be a priority. Prevention from COVID-19 can be achieved by following proper guidelines from concerned governmental authorities that includes wearing of mask, regular washing of hands and social distancing. In addition to these measures, focus should also be on individual immunity. AYUSH ministry has launched specific guidelines to enhance immunity. In lieu of that certain steps can be taken by individuals at home level in improving their immunity to fight infection. As we have seen that a number of natural products and home-based remedies have great therapeutic potential. Along with this, number of phyto-compounds from A. indica and T. cordiofolia has proved effective against SARS-CoV-2 through computational studies. Keeping these things in mind and easy availability of neem (A. indica) and giloy (T. cordiofolia) in Indian sub-continent, consumption of decoction (kadha)of these two can be effective in enhancing immunity and preventing infection. Consumption of decoction of neem and giloy can further prevent from certain post-COVID complications like hypertension, diabetes and body pains as these have been found to be effective against hypertension and diabetes (Gupta et al. 2017) in addition to other complications (Subapriya and Nagini 2005; Chowdhury 2020). So the combination of these can be a suitable preventory method, both during and post-COVID tenure.

Recently, incidence of mucormycosis has also been reported in COVID-19 patients, though the epidemiological factors and outcome is not well described at present (John et al. 2021). Critical COVID-19 patients require ventilatory support, use of corticosteroids and other adjunctive therapies. Long term use of steroid therapy can predispose patients to secondary bacterial and fungal infections. Conditions like uncontrolled diabetes mellitus, immunosuppression and corticosteroid therapy are potential risk factors for mucormycosis infection (Yusuf and Onyiriuka 2009; Ahmadikia et al. 2021). Though at present mucormycosis has become a point of focus, but COVID-19 patients are also prone to Aspergillosis, Candidiasis and Cryptococcosis (Song et al. 2020). Thus, focus should be more on prevention from such opportunistic pathogens which might show clinical manifestation as a consequence of current therapy.

It is a point of discussion whether such opportunistic fungal pathogens are affecting due to long term use of steroid therapy or due to some other yet unidentified factor. But considering this, primary focus should be on the use of medicinal plants because consumption of Amphotericin B (presently
recommended) for treatment of mucormycosis might lead to some other clinical manifestation. As a result, neem leaves which also possess antifungal properties (Subapriya and Nagini 2005) can be consumed with giloy in the form of decoction possessing vast therapeutic benefits. Thus, combination of these as decoction can be used both for prevention and during the course of COVID infection to keep such opportunistic pathogens at bay.

**Conclusion**

COVID-19 is responsible for respiratory tract infection, pulmonary fibrosis and multiple organ damage. Prevention from progression of infection and stabilization of initial symptoms could be achieved by consumption of natural products. Thus, natural products could act as beneficial supplements in the recovery of COVID-19 patients having pulmonary infection. Adverse side effects of drugs (antimalarial, retroviral drugs and corticosteroids) that are being repurposed in current pandemic have been reported in some clinical settings. Seeing the therapeutic potential of many natural products, these can be co-administered to reduce treatment-related side effects as they have no adverse effects compared to chemotherapeutic supplements. Different phytochemicals from neem and giloy have shown potential as a probable drug candidate through computational studies and knowing about vast therapeutic benefits of both, decoction of these can be used for prevention and recovery from COVID-19 by the time further research is done on their efficacy through clinical trials. These natural products with no side effect can help in preventing the complications of the ongoing treatment regime.

**Acknowledgements**

The authors are thankful to the respective Institutions. No funding was obtained to draft this review article.

**References**


Baidiya N, Khan AA, Ghosh NN, Dutta T,

Balkrishna A, Pokhrel S, Varshney A (2021a) Tinocordiside from Tinospora cordifolia (Giloy) may curb SARS-CoV-2 contagion by disrupting the electrostatic interactions between host ACE2 and viral S-protein receptor binding domain. Combinatorial Chemistry and High Throughput Screening 24: 1795-1802.


Fu Y, Cheng Y, Wu Y (2020) Understanding SARS-CoV-2-mediated inflammatory...


Kim SR, Jung YR, An HJ, Kim DH, Jang EJ, Choi YJ, Moon KM, Park MH, Park CH, Chung KW, Bae HR, Choi YW,


Sharma P, Dwivedee BP, Bisht D, Dash AK,


Weiss SR, Leibowitz JL (2011) Coronavirus


